U.S. Department of Commerce, Patent and Trademark Office					Atty Docket No.		Serial No.		
					PF-0510-1 CON		10/077,040		
LIST OF REFERENCES CITED BY APPLICANTS						Applicant(s)			
(Use several sheets if necessary)					Lal et al.				
The state of the s					Filing Date		Group		
25 0 8 2005 E					February 14, 2002		1649		
U.S. Patent Documents									
*Examiner		Document					Filing I	Date	
Initial		Number	Date	Name	Class	Subclass	If Appro	priate	
78	1	5,672,479	9:/30/97	Johnson et al.			RECE	IVED	
56	2	5,876,931	3/2/99	Holden			CFD 1	1 2002 -	
Foreign Patent Documents									
						TE	CH CENTER	14600/290	
		Document	Date	Country	Class	Subclass	Yes	No	
56	3	WO 99/40189	12 Aug.						
	OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
56	4	Rosa, P., and H.H. Gerdes, "The granin protein family: Markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors," J. Endocrinol. Invest., 17:207-225 (1994)							
((5	Ottiger, H.P. et al., "1B1075: A Brain- and Pituitary-Specific mRNA that Encodes a Novel Chromogranin/Secretogranin-like Component of Intracellular Vesicles," J. Neurosci., 10(9):3135-3147 (1990)							
11	6	Dopazo, A. et al., "Primary Structure of Mouse Secretogranin III and Its Absence from Deficient Mice," <u>J. Mol. Neurosci.</u> , 4(4):225-233 (1993)							
((7	Kingsley, D. et al. "Genetic ablation of a mouse gene expressed specifically in brain," The EMBO J., 9(2):395-399 (1990)							
((8	Holthuis, J. et al., "Secretogranin III Is a Sulfated Protein Undergoing Proteolytic Processing in the Regulated Secretory Pathway," <u>J. Biol. Chem.</u> , 271(30):17755-17760 (1996)							
. ((9	Hendy, G. et al., "REVIEW: Chromogranin A," <u>Clin. Invest. Med.</u> , 18(1):47-65 (1995)							
(1	10	Jensen, R. et al., "BRCAl is secreted and exhibits properties of a granin," Nat. Genet., 12:303-308 (1996)							
Examiner Stephen Gucker Date Considered 6/21/06									
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.								

LOP'S OF PAPERS ORIGINALLY FILED OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		THER ART (Including Author, little, Date, Pertinent Pages, Etc.)
0000	11	Lee, N. et al., "Comparative expressed-sequence-tag analysis of differential gene expression profiles in PC-12 cells before and after nerve growth factor treatment," Proc. Natl. Acad. Sci. USA , 92:8303-8307 (1995)
20 J. 2000	12	Dopazo, A. et al., GenBank Sequence Database, Accession AAA56636 (GI 413764), 7 Dec. 1994
W. Sales	13	Dopazo, A. et al., GenBank Sequence Database, Accession U02982 (GI 413763), 7 Dec. 1994
5	14	Rogister, B. et al., GenBank Sequence Database, Accession CAA69961 (GI 1771306), 8 Jan. 1997
56	15	Rogister, B. et al., GenBank Sequence Database, Accession Y08702 (GI 1771305), 8 Jan. 1997
56	16	Weis, K. et al., "The Endoplasmic Reticulum Calcium-binding Protein of 55 kDa Is a Novel EF-hand Protein Retained in the Endoplasmic Reticulum by a Carboxyl-terminal His-Asp-Glu-Leu Motif," <u>J. Biol. Chem.</u> , 269(29):19142-19150 (1994)
		RECEIVED
		SEP 1 U 2002
		TECH CENTER 1600/2900
		·
Examiner	tenh	In buck Date Considered 6/2/06
MPEP 609, D	raw li	l if reference considered, whether or not citation is in conformance with ne through citation of not in conformance and not considered. Include copy your communication to applicant.

DRIGINALLY FILED